ProCE Banner Activity

Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Podcast Episodes

In this podcast episode, experts Samuel Klempner, MD, and Gregory Botta, MD, PhD, discuss the rationale supporting claudin 18.2 as a therapeutic target and clinical considerations for related emerging therapies in the treatment of gastric and gastroesophageal cancers.

Released: March 28, 2023



Gregory Botta

Gregory Botta, MD, PhD

Clinical Professor of Medicine
Department of Medicine/Hematology & Oncology
University of California San Diego
La Jolla, California

Samuel Klempner

Samuel Klempner, MD

Associate Professor
Department of Medicine, Division of Hematology-Oncology
Mass General Cancer Center, Harvard Medical Center
Boston, Massachusetts

Provided by

ProCE Banner


This activity is supported by educational grants from


Bristol Myers Squibb

Faculty Disclosure

Gregory Botta, MD, PhD: consultant/advisor/speaker: Natera, TumorGen.

Samuel Klempner, MD: consultant/advisor/speaker: Amgen, Astellas, Exact Sciences, Merck, Mersana, Natera, Novartis, Sanofi-Aventis, Servier; stock/stock options: Nuvalent, Turning Point.